Home > Insider Trading > Filing (0001209191-13-031138)

Filing Details

Accession Number:: 0001209191-13-031138
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-06-07 12:50:04
Reporting Period:: 2013-06-05

Filing Date:: 2013-06-07
Accepted Time:: 2013-06-07 12:50:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1571498	Epizyme Inc.	EPZM	Pharmaceutical Preparations (2834)	261349956

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1288452	Bay City Capital Llc	750 Battery Street Suite 400 San Francisco CA 94111	No	No	Yes	No
1401826	Bay City Capital Fund V, L.p.	750 Battery Street Suite 400 San Francisco CA 94111	No	No	Yes	No
1409813	Bay City Capital Fund V Co-Investment Fund, L.p.	750 Battery Street Suite 400 San Francisco CA 94111	No	No	Yes	No
1461543	Bay City Capital Management V Llc	750 Battery Street Suite 400 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-06-05	3,426,762	$0.00	3,426,762	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2013-06-05	65,301	$0.00	3,492,063	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2013-06-05	163,549	$15.00	3,655,612	No	4	P	Indirect	See Footnotes
Common Stock	Acquisiton	2013-06-05	3,117	$15.00	3,658,729	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2013-06-05	10,280,288	$0.00	3,426,762	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-06-05	195,904	$0.00	65,301	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2013-06-05	17,666	$0.00	17,666	$25.73

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
17,666	2023-06-04	No	4	A	Indirect

Footnotes

Each share of Series B Preferred Stock was automatically converted into 1/3rd of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration.
Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V"), are deemed to be a "group" for the purpose of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V.
Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.
Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.
Not applicable.
Vests in full upon the earlier of (i) the expiration of the Dr. Goldfischer's initial term of office as a director of the Issuer, scheduled to occur on the 2015 annual meeting of the Issuer's stockholders and (ii) June 30, 2015. In the event of a change in control of the Issuer, the vesting schedule of the option will accelerate in full.
BCC and Management V have an arrangement with Dr. Goldfischer, the beneficial owner of the option, that provides such entities with a pecuniary interest in the option issued by the Issuer to Dr. Goldfischer. BCC and Management V each disclaims beneficial ownership in such option, except to the extent of their pecuniary interest therein.